IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Daratumumab Plus Bortezomib, Melphalan, and Prednisone (D-VMP) Vs VMP in NDMM Pts Ineligible for Transplant (ALCYONE) December 22, 2017 ASH A Phase 1b Study to Assess the Combination of Selinexor and Daratumumab in Patients with Relapsed / Refractory Multiple Myeloma December 19, 2017 ASH Development of a Prognostic Model That Predicts 3- and 5-Year Overall Survival in Multiple Myeloma Using the Connect® MM Patient Registry December 19, 2017 ASH Differential Effect of t(11;14) Abnormality on Survival and Depth of Response in African American (AA) and Non-AA Patients with NDMM in the Connect® MM Registry December 18, 2017 ASH Impact of Next-Generation Flow MRD Monitoring in Multiple Myeloma: Results from the Pethema/GEM2012 Trial December 18, 2017 ASH ASH 2016: Prospective Evaluation of 18F-FDG PET/CT As Predictor of Prognosis in Newly Diagnosed Transplant Eligible MM Patients December 3, 2016 ASH ASH 2016: Longitudinal FiSH at Primary Diagnosis and Relapse Reveals Clonal Evolution after ASCT in MM December 3, 2016 ASH Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice November 16, 2016 ASH Dr. Elena Zamagni on the role of FDG PET/CT in monitoring smoldering myeloma (ASH 2014) October 15, 2015 ASH Dr. Xavier Leleu on using Hevylite to monitor hypogammaglobulinemia in myeloma at (ASH 2014) October 15, 2015 ASH Dr. Stefan Knop on Stem Cell Transplant in Newly Diagnosed FISH-del13q Myeloma (ASH 2014) October 15, 2015 ASH Dr. Roman Hajek: Czech Myeloma Group study on models for progression from MGUS to myeloma (ASH 2014) October 15, 2015 ASH Load More
